**Supplemental table 3: Prognostic factors for overall survival in patients with metastatic grade 1 neuroendocrine neoplasms (cohort national cancer registry)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | N | UnivariableHR (95% CI) | P-value | Multivariable HR (95% CI) | P-value |
| Sex  |  |  |  |  |  |
| Male | 571 | Ref.  |  | Ref. |  |
| Female | 552 | 0.85 (0.72 – 1.00) | 0.047 | 0.83 (0.70 – 0.97) | **0.022** |
| Age |  |  |  |  |  |
| ≤65 | 582 | Ref. |  | Ref. |  |
| >65 | 541 | 2.14 (1.82 – 2.52) | <0.001 | 2.24 (1.90 – 2.65) | **<0.001** |
| Primary tumor |  |  |  |  |  |
| GE | 588 | Ref. |  | Ref. |  |
| Pancreas | 138 | 1.64 (1.28 – 2.09) | <0.001 | 1.73 (1.35 – 2.23) | **<0.001** |
| Lung | 77 | 2.01 (1.50 – 2.87) | <0.001 | 2.45 (1.70 – 3.53) | **<0.001** |
| Other | 10 | 1.18 (0.49 – 2.87) | 0.71 | 0.97 (0.40 – 2.38) | 0.95 |
| Unknown | 310 | 2.04 (1.70 – 2.45) | <0.001 | 1.89 (1.57 – 2.29) | **<0.001** |
| Number of organs with metastases |  |  |  |  |  |
| 1 | 683 | Ref. |  | Ref. |  |
| 2-3 | 421 | 1.55 (1.32 – 1.82) | <0.001 | 1.19 (0.96 – 1.47) | 0.12 |
| ≥4 | 19 | 1.46 (0.72 – 2.95) | 0.292 | 0.49 (0.20 – 1.19) | 0.11 |
| Location metastases |  |  |  |  |  |
| Liver | 814 | 1.61 (1.32 – 1.96) | <0.001 | 1.50 (1.19 – 1.89) | **0.001** |
| Brain | 12 | 2.32 (1.24 – 4.34) | 0.008 | 2.36 (1.20 – 4.65) | **0.013** |
| Lung | 95 | 1.30 (0.98 – 1.72) | 0.066 | 0.55 (0.31 – 0.96) | **0.035** |
| Bone | 130 | 1.47 (1.15 – 1.87) | 0.002 | 1.22 (0.90 – 1.64) | 0.20 |
| Lymph nodes (distant) | 233 | 1.22 (1.00 – 1.48) | 0.045 | 1.05 (0.83 – 1.34) | 0.67 |
|  |  |  |  |  |  |
| Liver\*Lung1 |  | - | - | 3.02 (1.57 – 5.79) | **0.001** |
| Lung\*Bone1 |  | - | - | 3.13 (1.47 – 6.65) | **0.003** |

*Abbreviations: HR = Hazard Ratio; 95% CI = 95% Confidence Interval; Ref. = Reference; GE = gastroenteral.*

*1Interaction terms included in the final multivariable model.*

*Events = 601.*